Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity

Inclusion criteria

• At least one hypersensitive tooth in everyday life after PAV 1 in-office visit
• At least one hypersensitive tooth in everyday life with a regular pain perception of at least 2 times per week after PAV 1 visit
• At least one tooth with dentine hypersensitivity to air stimulation → VAS ≥ 40mm at study entry
• Any sensitive tooth showing exposure of cervical dentine (gum recession) and no acute signs of caries on the exposed root
• For subjects entering the study at stage PAR-control: good healing of the periodontal surgery site, cause of pain must not be the result of the periodontal surgery
• Age ≥ 18 years and ≤ 75 years
• Willing and able to attend the on-study visits
• Willing and able to understand and to follow the study procedures and instructions
• Good oral hygiene throughout the study
• Written informed consent before participation in the study
• Subjects have undergone dental hygiene treatment immediately prior to study inclusion (except subjects entering the study at stage PAR-control)

Exclusion criteria

• Hypersensitivity only due to sweets
• Allergic reactions to any ingredients of InQpharm Mouthrinse e.g. chlorhexidine, zinc lactate
• Professional desensitizing therapy during the previous 3 months; GLUMA (glutaraldehyde/hydroxyethyl methacrylate) desensitizer application within 6 months
• Chronic systemic anti-inflammatory and analgesic medications
• Systemic disorders causing or predisposing to dental (e.g. dry mouth, reflux, eating disorders, etc.)
• Teeth or supporting structures with any other painful pathology or defect
• Subject with poor health conditions
• Concurrent participation in another clinical trial
• Pregnant or lactating women